




Healthcare News Roundup: BIopharmaceuticals
HSMN NewsFeed - 22 Jun 2022
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
HSMN NewsFeed - 21 Jun 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
HSMN NewsFeed - 15 Jun 2022
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
HSMN NewsFeed - 13 Jun 2022
STRM.BIO Appoints Vanessa Salazar as Vice President of Business Development
STRM.BIO Appoints Vanessa Salazar as Vice President of Business Development
HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 19 May 2022
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
HSMN NewsFeed - 17 May 2022
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.